Study Finds Semisynthetic Bile Acid Reduces Pro-Inflammatory Cells in Gut

A study conducted by researchers at the Medical University of Vienna has identified potential therapeutic effects of the semisynthetic bile acid NorUDCA on intestinal inflammation. The research indicates that NorUDCA suppresses the formation of pro-inflammatory T helper 17 cells (TH17) in the gut while simultaneously promoting the development of anti-inflammatory regulatory T cells. These findings suggest a possible new avenue for treating TH17-mediated intestinal diseases.

The study, recently published in the journal Gut, highlights NorUDCA’s dual role in modulating immune responses within the intestine. TH17 cells are known to contribute to inflammation and play a significant role in various autoimmune and inflammatory conditions affecting the gut. By inhibiting these cells and encouraging regulatory T cell activity, NorUDCA may offer therapeutic benefits for patients suffering from conditions such as inflammatory bowel disease (IBD). Researchers emphasize that further investigation is needed to explore its clinical applications fully.

Date: 13 March, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Breakthrough Study Suggests Common Antibiotic Vancomycin Could Treat Specific Inflammatory Bowel Disease Immune Cells Exhibit Dual Functional Roles in Defense and Attack Tests on Sunglasses Show Deficiencies in Protection Against Ultraviolet Rays PepGen’s New Drug Candidate Shows Promising Results in Treating Rare Muscle Disorder

Author

Mark Chiang

Ph.D in Biomedical Informatics Head of AI at GeneOnline